about
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasmsMolecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarrayHighly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarraysNUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicitySpontaneous improvement of chronic immune thrombocytopenia in children: experience of 56 patients at a single institute.Kasabach-Merritt phenomenon: a report of 11 cases from a single institution.SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations.Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemiaDeletion of the TNFAIP3/A20 gene detected by FICTION analysis in classical Hodgkin lymphomaSusceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.Allelotypes of lung adenocarcinomas featuring ALK fusion demonstrate fewer onco- and suppressor gene changes.Frequent inactivation of A20 in B-cell lymphomas.Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays.Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterationsMutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia.Exploration of the genetic basis of GVHD by genetic association studies.Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.Prognostic significance of leukopenia in childhood acute lymphoblastic leukemia.Simple evaluation method for CYP3A4 induction from human hepatocytes; The relative factor approach with an induction detection limit concentration based on the Emax model.Donor cell-derived hematological malignancies after allogeneic hematopoietic stem cell transplantation.Copy number analysis identifies tumor suppressive lncRNAs in human osteosarcoma.Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.Aberrant activation of ALK kinase by a novel truncated form ALK protein in neuroblastoma.High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.Oncogenic mutations of ALK kinase in neuroblastoma.Whole-genome profiling of chromosomal aberrations in hepatoblastoma using high-density single-nucleotide polymorphism genotyping microarrays.Transmission of chromosomally integrated human herpesvirus 6 via cord blood transplantation.Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.Case series of pediatric acute leukemia without a peripheral blood abnormality, detected by magnetic resonance imaging.Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.Long-term outcome of 6-month maintenance chemotherapy for acute lymphoblastic leukemia in children.Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: A study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation.Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body IrradiatiFavorable outcome in non-infant children with MLL-AF4-positive acute lymphoblastic leukemia: a report from the Tokyo Children's Cancer Study Group.No impact of high-dose cytarabine and asparaginase as early intensification with intermediate-risk paediatric acute lymphoblastic leukaemia: results of randomized trial TCCSG study L99-15.Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
P50
Q24595117-4EC752A1-3396-423C-AD09-441FEAAB3DBEQ24650855-915D5503-8BA8-4D9D-967B-09A7C42C71DAQ24676798-A68D5E03-9E34-492E-91A7-AE8C1321C378Q28115755-CC2CFCD0-513D-4895-B529-47F4D5E55B23Q33404073-59C6A943-DADF-4C7A-BF9E-4460B28EB0FCQ33405739-A7E74676-AF61-45B0-96EE-0F9492A97A3BQ33517413-FE81081F-44E0-4B00-B25E-869A684ADFCCQ34095608-85DA19CC-A2B8-4C22-9CAA-3223DA154849Q34435074-03BC000C-77F6-4D6A-870C-39B329DAF654Q34478851-F2DABA1C-52B0-4A8C-B4B7-2152803F40B5Q34536679-45491AE7-5683-45AE-942E-3A71B80BCDC2Q34607223-9F53C5AA-6E50-44F1-BB71-4B27D7694978Q35051968-8950EE2F-B6C9-4440-A501-D08BB5443F05Q35467835-EEB1FF98-2B61-4061-9B62-BEB89FBC5290Q35602127-2BA5CDB8-CA5E-454F-9795-EDAC61032417Q35863493-2A92D21B-B947-4514-81E2-D211D8552476Q37109353-162E885E-3A41-4ECD-B97E-4E0B6B5FC524Q37322911-727AFA98-FBC9-461A-A272-25ACB3ABB6FDQ37369396-8BFF04B4-1D39-4C0B-99EB-197266C8208AQ37398079-E6343E3D-186E-4FE7-B42C-007B85D6C860Q37652706-FD22DC0F-F51D-4C31-B525-83204A334FD0Q38618103-586F659D-4E56-440E-B540-6EB81EEBF08BQ38638242-4B089B6F-D4D6-48D5-A4B8-CA21BE6149FEQ38716475-8B711628-ADF7-4D76-85A6-FDFEBF0A16D0Q38864711-BF36E2CB-250B-4664-B1B6-5CA7B757EA8DQ39022777-44937AA5-EAE2-4341-9CBE-29B440BC01BBQ39411416-D0C6FCF8-9799-4600-9E4C-5FAF54751B9CQ39852653-634EBAE8-0AAA-4E6D-8E2C-2BBF04431711Q39928776-535462EB-2064-47D9-9FC5-F043562DB21DQ40013719-DC9A5163-505B-46A9-A6D9-B1DD47A9C56BQ40079621-898A5A47-13CD-4143-B52D-B6B513E7CBB2Q40126491-A16313A0-9479-4D11-BD7B-FD6FADF34500Q40327347-714FE6F9-D449-41EC-9213-2F1AE6185AACQ40513597-C270F31F-7BD2-4901-8491-AE2668D90E74Q40518805-4F512850-1933-41EF-9D51-15A9670EDE4DQ40858788-CC8F2B47-7908-44B1-A3C9-41E9DEA156F1Q41053934-1598B3EB-1D16-4F3F-AA5D-DB8D5B61C4C9Q41306896-28EB1483-315C-4565-AED9-D8324A2A358DQ42242801-B7EAC001-E70E-4A99-987D-0572C8E2D63CQ42795736-5B02AC18-3DB8-4E66-8E63-09091B7C831D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Motohiro Kato
@ast
Motohiro Kato
@en
Motohiro Kato
@es
Motohiro Kato
@nl
Motohiro Kato
@sl
type
label
Motohiro Kato
@ast
Motohiro Kato
@en
Motohiro Kato
@es
Motohiro Kato
@nl
Motohiro Kato
@sl
prefLabel
Motohiro Kato
@ast
Motohiro Kato
@en
Motohiro Kato
@es
Motohiro Kato
@nl
Motohiro Kato
@sl
P106
P21
P31
P496
0000-0001-5145-1774
P569
2000-01-01T00:00:00Z